1. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open‐label trial1. Issue 6 (29th December 2013) Authors: Arakaki, R. F.; Blevins, T. C.; Wise, J. K.; Liljenquist, D. R.; Jiang, H. H.; Jacobson, J. G.; Martin, S. A.; Jackson, J. A. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 6(2014:Jun.) Page Start: 510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Issue 8 (23rd June 2015) Authors: Blevins, T. C.; Dahl, D.; Rosenstock, J.; Ilag, L. L.; Huster, W. J.; Zielonka, J. S.; Pollom, R. K.; Prince, M. J. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 8(2015:Aug.) Page Start: 726 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Issue 2 (8th January 2016) Authors: Ilag, L. L.; Deeg, M. A.; Costigan, T.; Hollander, P.; Blevins, T. C.; Edelman, S. V.; Konrad, R. J.; Ortmann, R. A.; Pollom, R. K.; Huster, W. J.; Zielonka, J. S.; Prince, M. J. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 2(2016) Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗